Biologic response modifiers (BRMs) are substances that occur naturally in the body. They can also be manufactured in the laboratory and then administered as targeted therapy. Undoubtedly BRMs will find expanded role in terminal illness like cancer where other therapies have failed. However, great caution must be exercised in prescribing these agents in chronic indolent diseases where potential for ultimate harm might outweigh short-term benefits.
Copyright Â© 2011 Elsevier Inc. All rights reserved.